Population pharmacokinetics of nalbuphine after surgery in children by Bressolle, Françoise et al.
HAL Id: hal-02309688
https://hal.archives-ouvertes.fr/hal-02309688
Submitted on 9 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Population pharmacokinetics of nalbuphine after surgery
in children
Françoise Bressolle, Sonia Khier, A. Rochette, J.M. Kinowski, C. Dadure, X.
Capdevila
To cite this version:
Françoise Bressolle, Sonia Khier, A. Rochette, J.M. Kinowski, C. Dadure, et al.. Population pharma-
cokinetics of nalbuphine after surgery in children. British Journal of Anaesthesia, Oxford University
Press (OUP), 2011, 106 (4), pp.558-565. ￿10.1093/bja/aer001￿. ￿hal-02309688￿
Population pharmacokinetics of nalbuphine after
surgery in children
F. Bressolle1*, S. Khier1, A. Rochette2, J. M. Kinowski3, C. Dadure2 and X. Capdevila2
1 Pharmacokinetic Laboratory, Faculty of Pharmacy, BP 14491, Montpellier I University, 15 Avenue Ch. Flahault, 34093 Montpellier Cedex 5,
France
2 Department of Anesthesia and Critical Care ‘A’, Lapeyronie Hospital, 371 av du doyen G. Giraud, CHU de Montpellier, 34295 Montpellier
Cedex 5, France
3 Pharmacy Service, Care´meau Hospital, Rue du Prof. Janbreau, Nimes, France
* Corresponding author. E-mail: fbressolle@aol.com
Editor’s key points
† This study reveals
paediatric population
data for nalbuphine, an
opioid analgesic agent
widely used for control of
mild-to-severe pain.
† A two-compartment
allometric power model
developed in this study
best described the data.
† Allometric models in
children well described
the relationships
between clearances,
volumes of distribution,
and weight and might be
useful for dose
adjustments.
Background. Nalbuphine is an opioid analgesic agent widely used for control of mild-to-
severe pain. However, limited data are available on the pharmacokinetics of this drug in
children. The aim of this study was to characterize the population pharmacokinetics of
nalbuphine in patients with ages ranging from 1 to 11 yr and to identify patient
characteristics partially explaining inter-individual variability in nalbuphine
pharmacokinetic parameters.
Methods. Twenty-two children were included in this study. They received nalbuphine after
surgery by continuous infusion (loading dose, 0.2 mg kg21 over 10 min followed by
continuous infusion of 0.8 mg kg21 over 24 h). If pain relief was not adequate, 0.1 mg
kg21 bolus doses were allowed in 10 min. Eleven blood samples were collected per
patient. The data were analysed by non-linear mixed-effect modelling with the use of a
two-compartment structural model.
Results. Twenty patients completed the study. In the final model, the parameter values
were standardized for a body weight of 70 kg using an allometric model. Population
parameter estimates were: clearance 130 litre h21 70 kg21, inter-compartment clearance
75.6 litre h21 70 kg21, central volume of distribution 210 litre 70 kg21, and peripheral
volume of distribution 151 litre 70 kg21. In the children of this study, total clearance
expressed in litre h21 kg21 decreased significantly with increasing age and the
elimination half-life significantly increased.
Conclusions. The allometric power model developed in this study best reflected the data
and may be useful for dose adjustment.
Keywords: population pharmacokinetics; surgery, laparoscopy; children
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Nalbuphine hydrochloride [(2)-17(cyclobutylmethyl)-4,5a-
epoxymorphinan-3,6a,14-triol hydrochloride] is a synthetic
narcotic agonist–antagonist analgesic of the phenanthrene
series with a duration of analgesia of 4–5 h.1 It is structurally
related to narcotic antagonist, naloxone, and to the potent
narcotic analgesic, oxymorphone. Nalbuphine is used to
treat and prevent moderate to severe pain; it can also be
used for pain relief before and after surgery and during child-
birth. In adults with acute pain, its analgesic potency is
equivalent to that of morphine on a milligram basis.2 In
regard to morphine, nalbuphine could induce less respiratory
depression at high doses and less effect on arterial pressure.3
This drug undergoes an important hepatic metabolism in
humans giving N-hydroxycetocyclobutylmethyl nornalbu-
phine, the major metabolite, and hydroxylated derivatives.1
The estimated hepatic extraction ratio of nalbuphine is
0.5–0.7; thus, its hepatic clearance will be mainly dependent
on hepatic blood flow.4 5 Pharmacokinetic data of this drug
are limited; studies have been carried out in adults, children,
and neonates.4 6 – 8 It is well known that the pharmacoki-
netics of most drugs are age-dependent.9 – 11 Maturation of
metabolic pathways takes place at a different rate; the meta-
bolic clearance of drugs is usually very low at birth and then
increases to reach a maximum at about the age of 1 yr when
it can exceed that of adults. Simultaneously, water compart-
ments are significantly larger in children than in adults. Thus,
the treatment of postoperative pain by drugs extensively
metabolized in the liver raises a challenge to the clinician
who takes care of them.
Although nalbuphine has been approved for clinical use in
children, pharmacokinetic data of the drug remain very
limited. Nicolle and colleagues7 reported data for a few
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neonates whose mothers had received nalbuphine during
labour. Jacqz-Aigrain and colleagues8 have reported data
of a population pharmacokinetic study carried out in neo-
nates. These authors found that birth weight is a major
determinant of variability in nalbuphine disposition. Jaillon
and colleagues4 have shown that the elimination half-life
of nalbuphine is shorter in infants of 1.5–5 yr of age than
in those of 5–8.5 yr and that systemic clearance per kilogram
of body weight decreased with age. However, only seven
infants have been included in each group. The present
study was designed to provide data on pharmacokinetics of
nalbuphine in a paediatric population aged 1–11 yr old.
The purpose of this study was (i) to determine accurate
population pharmacokinetic parameters by using a two-
compartment open model; this model was parameterized
in terms of total clearance, central volume of distribution,
inter-compartment clearance, and peripheral volume of dis-
tribution, (ii) to accurately estimate both inter- and residual
variability in pharmacokinetic parameters, and (iii) to identify
which of the patient physiological parameters could have
influenced drug disposition. These data provide further valu-
able information regarding appropriate paediatric dosing.
Methods
Study design
The study protocol was reviewed and approved by the insti-
tutional review board. It was performed in accordance with
the legal requirements and the Declaration of Helsinki, and
with current European Community and US Food and Drug
Administration guidelines for good clinical practice. Written
informed consent was obtained from the parents or legal
guardians.
Twenty-two infants undergoing laparoscopic fundoplica-
tion for gastro-oesophageal reflux aged 1–11 yr were
included in this study. They were admitted in the department
of paediatric surgery of the Lapeyronie Hospital (Montpellier,
France). For all children, pre-anaesthetic data, anamnestic
data, physical examination, and standard laboratory tests
which included haematological and biochemical tests were
performed before and at the end of the study. Each subject’s
measurements of alanine aminotransferase, aspartate ami-
notransferase, bilirubin (direct bilirubinaemia ,2 mg dl21),
creatinine (creatininaemia ,1 mg dl21), red blood cell
count, white blood cell count, platelet count, haematocrit,
and haemoglobin were within normal ranges. Also children
receiving analgesics or anti-inflammatory drugs the week
before surgery were excluded. Anaesthesia was standardized
for all patients. Patients were fasting for 6 h. One hour before
surgery, they received midazolam (0.4 mg kg21) as rectal
premedication. Upon arrival in the operating theatre, stan-
dard monitoring equipment was applied, an i.v. line was
established, and anaesthesia was started with propofol
(4 mg kg21) and remifentanil (1 mg kg21). After tracheal
intubation, anaesthesia was maintained with sevoflurane
(1 MAC end-tidal concentration in 50% oxygen and air) and
remifentanil (0.4 mg kg21 min21). Neuromuscular block was
obtained with atracurium (0.5 mg kg21 to maintain a
train-of-four count of 1) at the beginning of surgery. A
second i.v. line was inserted into a femoral vein to facilitate
subsequent blood sampling. Central temperature was care-
fully maintained above 35.58C using a forced air system. Ven-
tilation was adjusted to maintain end-tidal CO2 between 30
and 35 mm Hg at the beginning of surgery. No further
change in ventilation was allowed during the study period.
At skin closure, remifentanil and sevoflurane were stopped,
end of neuromuscular block was assessed, and children
were allowed to breathe 100% O2 spontaneously. After
surgery, children received niflumic acid, a selective inhibitor
of cyclooxygenase 2, by rectal route (20 mg kg21 twice a
day), acetaminophen i.v. (30 mg kg21, four times a day),
and nalbuphine i.v. according to the following protocol: the
loading dose, 0.2 mg kg21, over 10 min was given at
wound closure followed by continuous infusion of 0.8 mg
kg21 over 24 h. In addition, 0.1 mg kg21 bolus doses were
allowed in 10 min if pain relief was not adequate, but no
more than twice within 1 h and no more than five times
for the 24 h study period. If pain remained unacceptable,
nalbuphine would be stopped and rescue analgesia would
be provided using i.v. morphine. Pain, evaluated every hour
and 30 min after each additional dose of nalbuphine, was
considered unacceptable when the Children and Infants
Postoperative Pain Score (CHIPPS)12 exceeded 2 on a
maximum of 10.
Blood sampling
It was planned to collect heparinized blood samples (2.5 ml)
from each patient at the following times: (i) immediately
before and (ii) at the end of the loading dose, (iii) 12 and
24 h after the beginning of i.v. infusion, and (iv) 0.25, 0.5,
1, 2, 4, 6, and 12 h after the end of infusion. Immediately
after collection, plasma was separated by centrifugation
(1500g) within 10 min and was frozen at 2308C until
assayed.
Nalbuphine assay
Nalbuphine was quantified in human plasma by high-
performance liquid chromatography using tandem-mass
spectrometry detection (LC-MS/MS). The internal standard
used was morphine. The LC system equipped with an auto-
sampler set at 48C was coupled to a PE Sciex API 365 quadru-
pole MS (Applied Biosystem MDS Sciex, Courtaboeuf, France)
with a turbo electrospray ion source that was operated in a
positive ionization mode with the nebulizer and TurboIonSpray
gases (nitrogen) set at 12 and 30 pounds per square inch (psi),
respectively. The voltage and temperature were maintained at
4500 V and 2508C, respectively. Nitrogen gas was used in a
collision-induced dissociation at a back pressure of approxi-
mately level 6. Nalbuphine was quantified via a multiple reac-
tion monitoring mode of the transitions at m/z 358.2340.2
for nalbuphine and m/z 286.2286.2 for morphine, with a
dwell time of 500 ms per transition. Optimized collision
energy of 10 eV was used for nalbuphine and 14 eV for
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morphine. The chromatographic separation was carried out on
a 30×5 mm (5 mm) reversed-phase Lichrospher ODS2 LC
column operating at room temperature (218C). An isocratic
mobile phase consisting of ammonium formate (1 mM)–
acetonitrile (80:20, v/v) containing 1% formic acid was used
at a flow rate of 0.3 ml min21. A 10 ml sample was injected
onto the column. Samples were extracted using the solid-
phase extraction (SPE) automate Aspec XL4 on Bond Elut
C18 (100 mg) cartridges. SPE cartridges were first conditioned
with 1 ml of methanol, 1 ml of distilled water, and 1 ml of Tris-
buffered saline solution (pH 7.5) and then plasma samples
were loaded onto the cartridges. The column was then
rinsed with 1 ml of distilled water. The elution was carried
out with 1 ml of a mixture of acetonitrile–water (80:20, v/v)
containing 1% formic acid. The organic phase was evaporated
under a stream of nitrogen at 408C. The peak area ratios (nal-
buphine/internal standard) varied linearly with concentration
over the range of 1–100 mg litre21. All calibration curves
were weighted according to the 1/x2 weighting scheme. The
method was precise (precision,≤12%) and accurate (recovery,
91–100%). Mean extraction efficiencies .80% for each
analyte were obtained. No significant matrix effects occurred.
Dilution has no influence on the performance of the method.
The lower limit of quantitation (LLOQ) was 1 mg litre21.
Pharmacokinetic analysis
Pharmacokinetic model-building analyses were performed
using the non-linear mixed-effects modelling (NONMEM)
software (version 5.1.1, Globomax LLC, Hanover, MD, USA)13
through the Visual-NM graphical interface.14 The following
covariates were considered pertinent to this study: patients’
age, body surface area, weight, height, gender, and the
ASA score (physical status classification system before
surgery). A two-compartment model fitted data better than
a one- or a three-compartment pharmacokinetic model.
This model was parameterized in terms of total clearance
(CL), central volume of distribution (V1), inter-compartment
clearance (Q), and peripheral volume of distribution (V2).
First-order conditional estimation was used to fit the
models because individual data sets were extensive.13 The
structural model was chosen on the basis of changes in
22 log-likelihood and on graphical analyses of the goodness
of fit. Because 22 log-likelihood is approximately x2 distribu-
ted and the addition of one compartment increases the
degree of freedom by a factor of 4, a change of 9.49 in 22
log-likelihood was required at the 5% significance level to
select the more complex model. Several error models were
compared: additive, exponential, or combined (additive+
exponential). It was found that residual variability was best
described by an exponential error model given below:
Cij(t) = f (Pj,Dij, tij) × exp(1ij) (1)
where Pj is the pharmacokinetic parameter of the subject j, tij
the time of the ith measurement, Dj the dosing history of the
subject j, f the pharmacokinetic model, and 1ij the residual
deviation of the model from the observations and contains
contributions from intra-individual variability, assay error,
and model misspecification for the dependent variable. 1 is
assumed to be a random Gaussian variable with mean zero
and variance of v21 . Inter-individual variability in pharmacoki-
netic parameters was assessed according to an exponential
error model; the Pj parameter of the jth subject was
described by the relationship:
Pj = Pmean × exp(hP) (2)
where Pj is the pharmacokinetic parameter of subject j, Pmean
the population pharmacokinetic parameter, and hP a
Gaussian random variable with mean zero and variance ofv2hP.
Individual parameters were calculated as empirical Bayes
estimates using the POSTHOC option in NONMEM. Several
secondary pharmacokinetic parameters were calculated
from the individual primary pharmacokinetic parameters:
the volume of distribution at steady-state (Vss) and the half-
life (t1/2) of the terminal part of the curves.
After selection of the best basic pharmacostatistical
model, both a traditional approach and an allometric
scaling were used to test the influence of covariates. In a
first step, the relationships between the individual pharma-
cokinetic parameters and the above-mentioned covariates
were investigated graphically. Covariates showing a strong
correlation with a pharmacokinetic parameter were then
separately incorporated in the population model and tested
for statistical significance. Both linear functions and power
models were tested (covariates being centred or not
around the mean values). The effect of each covariate was
assessed by the likelihood ratio test, based on the difference
in the objective function values between hierarchical models.
The forward inclusion and backward elimination method was
applied for covariate model development.
In a second step, allometric scaling15 – 17 was also tested
to assess the influence of weight on CL, Q, V1, and V2:
Paramj = Paramstd ×
WTj
WT70 kg
[ ]g
(3)
with g¼0.75 for clearances and g¼1 for volumes of distri-
bution. In this equation, Paramj is the parameter in the jth
individual with a weight of WTj and Paramstd the parameter
in an individual with a weight of 70 kg (WT70 kg).
Quality of fit
Criteria for model selection included visual inspection of
goodness-of-fit plots [i.e. measured concentrations (DV) vs
population (PRED) and individual predictions (IPRED);
weighted residuals (WRES) vs PRED; and WRES vs time after
administration]. The performance of Bayesian estimation
was assessed by examining the prediction error (PE); PE
was defined as [(DV–IPRED or PRED)/IPRED or
PRED]×100%. Both MDPE (median of all PEs) and MDAPE
(median of all absolute PEs) were calculated.
Nalbuphine pharmacokinetics in children BJA
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Using the final covariate model, the visual predictive
checks (VPCs) were carried out by simulating 1000 virtual
data sets to assess the performance of the model. This
analysis was performed using the R program. The 5th, 50th
(population median response), and 95th percentile concen-
trations were plotted against time post-dose and the
patients’ data were superimposed.
Simulations
We selected an average concentration of 12 mg litre21 as the
therapeutic concentration for the design of an effective
dosing regimen for nalbuphine. This concentration corre-
sponds to the mean steady-state plasma concentration
observed in this study. Simulations were performed using
parameters of the final model to determine the optimal
treatment schedule of nalbuphine needed to maintain this
concentration. Typical patients of weight 10 kg (1–2 yr old),
13 kg (2–5 yr old), and 24 kg (5–11 yr old) were assumed
for simulation purposes. Moreover, we have characterized
the pharmacokinetics of elimination of nalbuphine in terms
of the 20%, 50%, and 80% context-sensitive decrement
times.
Validation of the final model
The bootstrap resampling procedure was used for evaluating
the stability and robustness of the final model.18 The boot-
strap resampling was repeated 1000 times to evaluate
whether an appreciable discrepancy existed between the
parameter values estimated from the original data and the
estimated bootstrap mean values. Final population par-
ameters were compared with those obtained from the
1000 bootstrap analyses.
Results
All patients received planned continuous analgesia and no
therapeutic failure (i.e. shift to morphine) was observed.
There were 14 patients (63.6%) who required at least one
additional bolus of nalbuphine. This first bolus was given at
a mean time of 2.2 h after surgery (SD: 2.3 h). Nine patients
(41.0%) received a second bolus at 7.4 h, seven received a
third bolus at 10.0 h, three a fourth bolus at 12.6 h, and
one a fifth bolus at 19.8 h. All resulted in a decrease in
CHIPPS from 6.5 down to 0.7 within 30 min. Drowsiness
was observed in seven patients (31.8%), nausea in three
(13.6%), and urinary retention in three. Out of 22 children
enrolled in the study, two were excluded for lack of blood
samples. Baseline patient characteristics of the 20 children
(six girls and 14 boys) who completed the study are pre-
sented in Table 1. Eight children had an ASA score of I, 10
had an ASA score of II, and two had an ASA score of III.
Depending on the patient, 4–6 h after the end of infusion,
nalbuphine concentrations were below the LLOQ of the
analytical method. Therefore, a total of 157 plasma concen-
tration measurements were included in the analysis.
A decrease in the objective function of 60.6 is associated
with the use of a two-compartment model compared with
a one-compartment model. The use of a three-compartment
model led to failure in model convergence. Before covariate
inclusion (Step 1), population pharmacokinetic parameters
are summarized in Table 2. During covariate analysis, two
models gave good results: (i) the addition of weight and
age on CL [CL¼weight×(2age×u1+u2)] and age on V1
[V1=u3× age/4.2
( )u4 ] to the base model produced a
decrease in objective function of 44.6 units; and (ii) the use
of allometric scaling results in an improvement of the objec-
tive function of 39.3 units. For both models, the fits to the
data were excellent and the differences were relatively
small. As the first model has two more parameters than
the allometric model, it is not statistically better. Moreover,
criteria on the quality of fit were slightly better for the allo-
metric model. Thus, this model was selected as the final
model.
The estimated population parameters of nalbuphine in
the final model are shown in Table 2. It was not possible to
estimate population parameter variability on V2. The ratios
of the between-subject variance predictable from covariates
to the total population parameter variance obtained without
covariate analysis are presented in Table 3. Inclusion of body
weight decreased the variance of CL and V1, but increased
the variance of Q. A reason may be that there is no v for
V2 (having a large variance of 0.473 in the basic model) in
the allometric model, so that the high variance of Q may in
part be attributable to V2. Results presented in Table 3 indi-
cate that 39% and 65% of the overall variability in V1 and
CL are predictable from covariate information, respectively.19
Mean pharmacokinetic parameters of nalbuphine in the 20
children who completed this study are presented in Table 4.
The elimination half-life of nalbuphine increased with age
(from 1.7 h in 1- to 2-yr-old children to 3.5 h in 7–11 yr
old) and the CL in litre h21 kg21 decreased (from 3.3 to 2.2
litre h21 kg21, in the two groups, respectively; Fig. 1).
The goodness of fit has been evaluated by comparing the
regression line estimated on the DV vs IPRED values [slope:
1.04, 95% confidence interval (CI): 0.99–1.06; intercept:
20.57 mg litre21, 95% CI: 21.4 to 0.023] to the reference
line of slope¼1 and intercept¼0, and no significant differ-
ence occurred (Supplementary Fig. S1A). Likewise, the slope
of the regression line DV vs PRED was not statistically differ-
ent from 1 and the intercept was not statistically different
from 0 (slope: 1.04, 95% CI: 0.97–1.10; intercept: 20.20 mg
litre21, 95% CI: 21.63 to 1.22) (Supplementary Fig. S1B).
Moreover, adequate plots were observed in the final model
Table 1 Patient characteristics. CI, confidence interval
Age (yr) Weight
(kg)
Height (cm) Body surface
area (m2)
Mean 4.2 15.6 97.6 0.64
95% CI 3.0–5.4 12.4–18.7 90.3–104.9 0.56–0.72
Maximum 11 34.0 137 1.0
Minimum 1 7.2 74 0.39
BJA Bressolle et al.
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between weighted residuals and predicted concentrations
(Supplementary Fig. S1C). The vast majority of the weighted
residuals lay within 2 units of perfect agreement and were
symmetrically distributed around the zero ordinate; no sys-
tematic deviations were observed. For the final model, the
MDPE and MDAPE of the population predictions PRED were
20.40% and 22.8%, respectively (Table 2). These values
were in a typical range for pharmacokinetic models. The
plot of PEs vs time shows random distribution around the
zero ordinate (data not shown). The VPC plot (Fig. 2) confirms
the adequacy of model predictions, showing no apparent
deviations between model and data. About 95% of the
data fit well within the 5th–95th percentiles band and the
Table 2 Population pharmacokinetic parameters of nalbuphine. IIV, inter-individual variability; SE, standard error of estimate expressed as
coefficient of variation; s, residual variability; CL, total clearance; V1, initial volume of distribution; V2, peripheral volume of distribution; Q,
inter-compartment clearance; PEs, prediction errors; MDPE, median of all PEs; MDAPE, median of all absolute PEs; DV, observed
concentrations; IPRED, individual predicted concentrations; PRED, population predicted concentrations
Basic model Final covariate model (allometric model)
Mean (SE, %) IIV,% (SE, %), shrinkage, % Mean (SE,%) IIV,% (SE,%), shrinkage, %
Population parameters
CL (litre h21) 41.6 (9.4) 31.2 (39.9), 13.6
CL (litre h21 70 kg21) 130 (5.1) 18.4 (36.7), 7.86
V1 (litre) 39.9 (8.5) 39.1 (38.3), 37.0
V1 (litre 70 kg
21) 210 (8.7) 30.7 (53.1), 28.5
V2 (litre) 27.9 (19.7) 68.8 (57.5), 28.6
V2 (litre 70 kg
21) 151 (14.0) Not estimated
Q (litre h21) 15.7 (36.6) 22.4 (28.7), 44.7
Q (litre h21 70 kg21) 75.6 (35.2) 34.8 (53.5), 34.4
s (%) 24.7 (18.0) 24.1 (21.4)
MDPE (%)
(DV vs IPRED) 21.78 0.17
(DV vs PRED) 3.70 20.40
MDAPE (%)
(DV vs IPRED) 10.7 11.3
(DV vs PRED) 28.3 22.8
CL
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Fig 1 Scatter plots showing the relationship between individual
weight-normalized CL values and age.
Table 4 Mean pharmacokinetic parameters of nalbuphine in the
20 children of this study undergoing laparoscopic fundoplication.
IIV, inter-individual variability; CL, total clearance; V1, initial
volume of distribution; V2, peripheral volume of distribution; Q,
inter-compartment clearance; Vss, steady-state volume of
distribution; t1/2, half-life of the terminal part of the curve
Mean IIV (%)
CL (litre h21) 41.0 35.1
V1 (litre) 47.3 51.1
V2 (litre) 34.0 48.3
Q (litre h21) 24.1 33.5
Vss (litre) 81.3 48.0
t1/2 (h) 2.7 18.3
Table 3 Effect of covariate analysis on variance (v2). PPV2, total
population parameter variance obtained without covariate
analysis; BSVP2, between subject variance predictable from
covariates; BSVR, random between subject variance estimated
when covariate analysis is included; CL, total clearance; V1, initial
volume of distribution; V2, peripheral volume of distribution; Q,
inter-compartment clearance
PPV2 BSVP2 BSVR BSVP2/PPV2
CL 0.0979 0.0641 0.0338 0.65
V1 0.153 0.059 0.0941 0.39
V2 0.473 Not estimated
Q 0.050 20.071 0.121 21.42
Nalbuphine pharmacokinetics in children BJA
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data were symmetrically distributed around the median. The
time–concentration profile (with 90% CI) for a 4-yr-old child
weighing 16 kg is presented in Figure 3.
Table 5 presents (i) the simulation results for different
ages and weights to obtain a target concentration of 12 mg
litre21 and (ii) context-sensitive decrement times for 20%,
50%, and 80% concentration decrement. These dosing sche-
dules result in 85% of simulated subjects having concen-
trations above 12 mg litre21 at steady state (between 12
and 15 mg litre21). Three children of 1, 1.5, and 7.2 yr have
steady-state nalbuphine concentrations of 9.7, 8.8, and 8.3
mg litre21, respectively.
The final model was fitted repeatedly to 1000
bootstrap-resampled data sets. Less than 6% of bootstrap
runs were unsuccessful. The average parameter values
obtained from the bootstrap analyses and the final estimates
from the original data set are compared in Table 6. These
results indicated that the reliability and robustness of the
parameter estimates and thus the population pharmacoki-
netic model was acceptable.
Discussion
The present study was undertaken in the light of the limited
information regarding pharmacokinetics of nalbuphine in
children.4 7 8 With the exception of neonates,8 these pub-
lished studies have been performed in a limited number of
subjects.4 7 Both NONMEM and non-parametric expectation
maximization methods have been used for population phar-
macokinetic modelling in children. In this study, nalbuphine
population characteristics were estimated using NONMEM.
This population modelling method described nalbuphine
data well. Different pharmacokinetic models were tested;
the structural model was chosen on the basis of the
changes in 22 log-likelihood and qualitative assessment of
diagnostic plots. Contrary to the findings reported by
Jacqz-Aigrain and colleagues,8 a two-compartment model
was found to fit the data satisfactorily. This model was in
agreement with that published by Jaillon and colleagues.4
The number of patients finally included in this study was
20. In infants having about the same age, there are
marked inter-patient variations in weight (e.g. in patients
between 3 and 4 yr of age, the body weight ranged from 8
to 15 kg). These results were in agreement with those
reported by Jacqz-Aigrain and colleagues8 in neonates. It
has been suggested that the use of allometric models in
1
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Typical child: 4 yr, 16 kg
Loading dose, 4 mg
Maintenance dose, 16 mg
Css, 13.7 µg litre–1
Fig 3 Time–concentration profile for a child aged of 5 yr and
weighing 20 kg. The dashed lines represent the 90% CIs. Css,
steady-state plasma concentration
Table 5 Dosing regimens that attain a target concentration of 12 mg litre21 at steady-state and context-sensitive decrement times
Age (yr) Mean weight (kg) Loading dose over 10 min (mg) Maintenance dose over 24 h (mg) Context-sensitive
decrement times
(min)
% concentration
decrement
20 50 80
Range, 122; mean, 1.5 10 0.40 (0.040 mg kg21) 9.6 (0.960 mg kg21) 19 54 168
Range, .225; mean, 3.5 13 0.65 (0.050 mg kg21) 12.1 (0.931 mg kg21) 22 62 193
Range, .5211; mean, 7.5 24 1.10 (0.046 mg kg21) 16.0 (0.666 mg kg21) 25 80 246
Time (h)
N
a
lb
up
hi
ne
 (µ
g l
itr
e–
1 )
0 5 10 15 20 25 30
120
100
80
60
40
20
0
Fig 2 VPC plot for the studied population. The middle line depicts
the model predicted median. The other lines (above and below
the median) present the 5th and 95th percentiles. The grey
area depicts the range between the 1th and 99th percentiles.
Black dots are observations.
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children well described the relationships between clearances
and weight and volumes of distribution and weight.15 – 17 19
In the current study, different covariate models were exam-
ined: the traditional approach using a linear or power model
and the allometric model. The best results were obtained
using the allometric model. Such a parameterization avoids
additional parameters in the model and allows a comparison
of children parameter estimates with those reported in
adults and neonates. A large proportion of the parameter
variability (39% and 65% of the overall variability in V1 and
CL, respectively) can be attributable to the inclusion of
weight in the model. In our population of children, the
mean CL was 41.0 litre h21, mean Vss was 81.3 litre, and
mean t1/2 elimination was 2.7 h. After weight adjustment,
CL was 2.78 litre h21 kg21 and Vss was 5.5 litre kg
21.
Similar CL values were found by Jaillon and colleagues4 in
infants (1.5–8.5 yr). As reported by these authors, systemic
clearance of nalbuphine expressed in litre h21 kg21
decreased significantly with age (Fig. 1) and the elimination
half-life significantly increased. At the age of 11 yr, children
have a CL about two times lower than at the age of 1 yr.
In the present study, Vss and the elimination half-life were
1.5–2 times higher than that reported by Jaillon and
colleagues.4
The population model developed in this study predicts nal-
buphine plasma concentrations accurately and with good
precision as evidenced by small MDPE and MDAPE values
(20.4% and 22.8%, respectively) and the results of the VPC
plots. The result of bootstrap analysis validation indicated
that the reliability and robustness of the parameter esti-
mates and thus the population pharmacokinetic model was
acceptable.
Patients who completed the study received administered
doses of nalbuphine ranging from 1 to 1.4 mg kg21 day21
(mean, 1.12 mg kg21 day21) including one to four additional
bolus doses required in 14 children to maintain adequate
pain relief. The bolus dose at the initiation of treatment
ranged between 0.18 and 0.21 mg kg21 (mean, 0.2 mg
kg21), reaching a mean nalbuphine plasma concentration
of 63.3 mg litre21. The maintenance dose ranged between
0.73 and 0.83 mg kg21 (mean, 0.8 mg kg21). The
maximum dose of 1.4 mg kg21 day21 was administered to
two children of 4.1 and 5.5 yr old. For simulations, we have
selected an average concentration of 12 mg litre21 as the
therapeutic concentration for nalbuphine. It is remarkable
that in most of the patients who required additional bolus
doses, the nalbuphine concentrations were lower than 10
mg litre21. Moreover, the majority of these patients had
maintenance doses lower than those predicted from simu-
lated data. For a typical 3.5-yr-old child, weighing 13 kg, an
initial bolus dose of 0.050 mg kg21 nalbuphine and a main-
tenance dose of 0.931 mg kg21 over 24 h achieve and main-
tain the steady-state plasma concentration of 12 mg litre21.
Overall, the treatment was well tolerated by the children and
none of them required morphine rescue analgesia.
Patients of this study received co-administration of mida-
zolam, propofol, remifentanil, sevoflurane, and acetamino-
phen. Nalbuphine is metabolized via cytochrome P-450 3A4
(CYP3A4) and 2C19.20 CYP3A4 is responsible for the metab-
olism of numerous therapeutic drugs including midazolam
and acetaminophen.21 22 Anaesthetic agents—remifentanil,
propofol, and sevoflurane—were selected to avoid clinical
interference with pain evaluation and proved rapid elimin-
ation. Midazolam also had a short elimination half-life,
between 1.5 and 2.5 h and was given at least 3 h before nal-
buphine.23 Acetaminophen was administered after surgery,
four times a day; it is likely that therapeutic blood levels
are much higher than those of nalbuphine. Thus, a risk of
non-competitive inhibition of the metabolism of nalbuphine
by acetaminophen, as previously reported for fentanyl,24
might occur. However, in clinical practice, acetaminophen is
routinely associated with opioid analgesics as part of multi-
modal analgesic procedures; nalbuphine–acetaminophen
drug interactions have never been reported. Concerning the
other co-administered drugs, there is no risk of pharmacoki-
netic interactions.
In conclusion, we reported for the first time the results of
a population pharmacokinetic analysis carried out in children
to estimate individual pharmacokinetic parameters of nalbu-
phine. This study demonstrates the importance of consider-
ing and incorporating weight as a covariate in order to
adequately describe the drug behaviour. The allometric
power model developed in this study best reflected the
data and may be useful for dose adjustment.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
Table 6 Bootstrap validation of the estimated population
pharmacokinetic parameters in the final model
Parameters Original data 1000 bootstrap
replicates
Mean
estimate
2.5%
quantile,
97.5%
quantile
Mean
estimate
2.5%
quantile,
97.5%
quantile
CL (litre h21) 130 115, 145 131 118, 144
V1 (litre) 210 166, 255 208 164, 251
V2 (litre) 151 129, 173 153 128, 180
Q (litre h21) 75.6 55.0, 96.2 75.8 54.6, 96.9
Inter-individual variability
v2CL 0.0338 0.0140,
0.0536
0.0324 0.0128,
0.0613
v2V1 0.0941 0.0405,
0.148
0.0929 0.0436,
0.142
v2V2 Not estimated
v2Q 0.121 0.0280,
0.215
0.123 0.0272,
0.218
Residual
variability, s2
0.0580 0.0353,
0.0807
0.0563 0.0340,
0.0841
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